INSIDE INDUSTRY
Abstract
Drug development companies in APAC need to raise their game to capitalise on the $33bn+ immuno-oncology treatment opportunity
Singapore’s pharmaceutical market value to reach $1.15 billion by 2021
Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients
FDA approves Amgen’s Repatha (evolocumab) to prevent heart attack and stroke
FDA approves first drug for rare disease, eosinophilic granulomatosis with polyangiitis
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss
Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer
Globavir announces partnership with Singhealth Duke-NUS Academic Medical Centre to study dengue treatment
Mundipharma secures exclusive license for the development and commercialisation of PAION’s remimazolam in Japan
- Drug development
- APAX
- immune-oncology
- Singapore pharmaceutical market
- ryzodeg
- hypoglycaemia
- type 2 diabetic fasting
- FDA
- amgen
- repatha
- eosinophilic granulomatosis with polyangiitis
- churg-strauss syndrome
- biosimilar
- cervical cancer
- stomach cancer
- gene therapy
- inherited vision loss
- luxturna
- Samsung Medical Center
- A*Star
- IMCB
- NCCS
- NUS
- hepatocellular carcinoma
- liver cancer
- SingHealth Duke-NUS Academic Medical Centre
- Globavir Biosciences
- infectious diseases
- dengue
- chikungunya
- Mundipharma
- PAION
- ICU sedation
- general anesthesia
- remimazolam
